Skip to Main Content
Contribute Try STAT+ Today

Biotech innovations dominate the life science news cycle — think CRISPR for gene editing or CAR-T for cancer immunotherapy. Medical technologies, encompassing the broad swath of devices and interventional technologies, diagnostics, imaging, and digital medicine, tend to make their marks out of the limelight, yet have an enormous impact on public health and offer significant investment opportunities.

Take, for example, the trajectory of interventional cardiology. Open-heart surgery was long considered the only way to restore blood flow limited by a blockage in a coronary artery. The invention of artery-opening angioplasty not only changed that but, along with significant improvements in surgery overall, contributed to a steep decline in deaths due to cardiac disease. Abetting this decline were advances in engineering minimally invasive techniques, better diagnostic stratification of patients for surgery or interventional approaches, and a rise in improvements in anesthetic monitoring and critical care support. The result is good news for people with acute and chronic cardiac conditions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.